ClinicalTrials.Veeva

Menu
U

Unity Clinical Research | Oklahoma City, OK

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Rocatinlimab
ASN002
Deucravacitinib
LY3471851
BI 655130
Spesolimab
Remibrutinib
BMS-986165
CX11
Dupilumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 29 total trials

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in pa...

Enrolling
Hidradenitis Suppurativa
Drug: Placebo 1
Drug: Placebo 2

This study is testing whether a new medication called CX11 works and is safe for participants with type 2 diabetes who have not reached good blood su...

Not yet enrolling
Type II Diabetes Mellitus
Other: Placebo
Drug: CX11

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Active, not recruiting
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

This is a US, multi-center, randomized, double-blind, double-dummy, Phase 3b study to evaluate efficacy of remibrutinib (25 mg twice daily \[b.i.d.\]...

Enrolling
Chronic Spontaneous Urticaria (CSU)
Drug: Placebo solution for injection
Drug: Dupilumab

The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are:*...

Active, not recruiting
Plaque Psoriasis
Drug: Placebo
Drug: Apremilast

The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic der...

Enrolling
Atopic Dermatitis
Drug: PF-07275315
Other: Placebo
Locations recently updated

A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis

Enrolling
Plaque Psoriasis
Drug: Ustekinumab
Drug: Deucravacitinib

The main purpose of this study is to evaluate the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in participants who have bee...

Active, not recruiting
Psoriasis
Drug: Placebo
Drug: BMS-986165

The purpose of this study is to evaluate the maximal use of ruxolitinib cream in adult and adolescent participants with hidradenitis suppurativa.

Enrolling
Hidradenitis Suppurativa
Drug: Ruxolitinib Cream

Trial sponsors

Boehringer Ingelheim logo
Amgen logo
Bristol-Myers Squibb (BMS) logo
A
Indivior logo
Lilly logo
Nektar Therapeutics logo
Novartis logo
A
AbbVie logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems